Pacific Biosciences of California PACB Service — Deferred revenue, current
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's service — deferred revenue, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's service — deferred revenue, current?
- Pacific Biosciences of California (PACB) reported service — deferred revenue, current of $16.3M in Q1 2026.
- How has Pacific Biosciences of California's service — deferred revenue, current changed year-over-year?
- Pacific Biosciences of California's service — deferred revenue, current increased by 7.2% year-over-year, from $15.2M to $16.3M.
- What is the long-term trend for Pacific Biosciences of California's service — deferred revenue, current?
- Over 2 years (2021 to 2025), Pacific Biosciences of California's service — deferred revenue, current has grown at a 24.8% compound annual growth rate (CAGR), from $39.9M to $62.1M.
- What does service — deferred revenue, current mean?
- This represents the portion of service-related payments received in advance that are expected to be recognized as revenue within the next twelve months. It serves as a leading indicator of near-term service revenue stability and customer retention for the company's installed base. A growing balance typically suggests strong demand for ongoing support and maintenance contracts.